Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04522544 |
| Title | Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC |
| Acronym | IMMUWIN |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DEU |